Fatal epidural infusion - call for a system-wide change by Cyna, A. et al.
Anaesthesia and Intensive Care, Vol. 30, No. 1, February 2002
Anaesth Intensive Care 2002; 30: 99-103
Correspondence
Fatal epidural infusion—call for a 
system-wide change
In the U.K. this year, deaths of patients have been
reported following inadvertent administration of
intravenous (IV) medications into the intrathecal
space1 and inadvertent administration of an epidural
solution into the intravenous compartment2. A
patient in an Australian hospital receiving an epidural
infusion which was confused with an intravenous one,
has been reported as leading to yet another fatality3,4.
In our own institution we have recently experienced
an incident where a woman, post caesarean section,
received an epidural injection of cephalothin that was
intended for IV administration. Training, experience,
protocols and being careful when administering
medications all help, but despite our best efforts,
humans are fallible and error is inevitable5. The
common coupling of intravenous, epidural and spinal
equipment allows the possibility of administering
drugs, intended for the IV route, into epidural or
intrathecal access ports and vice versa. This common
coupling conforms to the luer design, consisting of 
a 6% conical taper in both a slip fit and a lockable-
screw-thread configuration as described in the
Australian Standards (AS 1600.1 1998). The sim-
plicity in use and construction of this system is
attested to by its adoption on a global scale. An
important patient safety problem is now being
increasingly recognised5,6 and calls for a luer in-
compatible system for some aspects of regional
equipment are coming from a variety of sources5-7.  
If confronted today with epidural and spinal anaes-
thesia as completely new techniques, it is hard to
imagine that any regulatory or professional body
would countenance their introduction using com-
patible equipment. We would envisage that an alter-
native coupling/tubing to the luer system should
constitute the interface between all components
associated with regional drug administration. This
should include epidural/spinal needle hubs, filters,
drawing-up cannulas, minimum volume extension
tubing and syringes. 
Our proposed solution—the Adelaide Regional
Connector (ARC)—is currently under prototype
development and is shown in Figure 1. Figure 1(a)
shows the current luer system with the 6% taper and
a male component of 3.967 mm external diameter
and corresponding female connection. Figure 1(b)
demonstrates the ARC with a smaller 3.5 mm male
component that retains the 6% taper. It should be
noted that an essential feature of this design is the
presence of an encircling collar around the male
element. The figure demonstrates a screw thread for
locking but this may be considered optional. The
incompatibility of the ARC with the current luer
FIGURE 1: (a) The current luer system with the 6% taper and a
male component of 3.967 mm external diameter and correspond-
ing female connection. (b) ARC with a 3.500 mm male component
and which retains the 6% taper. Note presence of an encircling
collar around the male element. (c) Standard male luer connection
is too large to engage the female element of ARC. (d) The male
ARC component is unable to engage the standard female luer con-
nection because of the presence of the collar around the smaller
male element.
system is demonstrated in Figure 1(c) and 1(d).
Figure 1(c) shows a standard luer connection being
too large to engage the female element of the ARC.
Figure 1(d) demonstrates that the male ARC compo-
nent is unable to engage the standard luer female
connection because of the presence of the collar
around the smaller male element. The plunger of the
ARC syringe is colour-coded to readily distinguish it
from the current standard hypodermic syringe. In
addition, the ARC syringe barrel is clearly labelled
“Not for IV use”.
Specific infusion pumps for regional anaesthesia
tubing are currently available. It should not be diffi-
cult to ensure that these cannot be interfaced, or used
at rates associated, with intravenous equipment. We
would also propose that, in line with this develop-
ment, drugs for regional use might be packaged in
such a way that only regional coupling systems could
access them.
Although anaesthetists represent the largest
specialty using regional equipment, this safety issue 
is relevant to all practitioners administering medica-
tions into the intrathecal or epidural space, such as
interventional radiologists, critical care personnel
and haematologists. Implementation of the required
modifications to current regional equipment on the
scale required will necessarily involve many stake-
holders, including national and international regula-
tory bodies and the medical supplies industry7. This
process will present numerous challenges, the most
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Vasopressin and Shock
I read with interest the review article “Vasopressin
and Shock”1.
Forrest notes that patients in shock are sensitive to
low doses of vasopressin, but does not elaborate on
the reasons for this, of which there are several.
As plasma concentrations of vasopressin are noted
to be low in the shock state, it is likely there is
increased receptor availability for the exogenously
administered hormone. Also, sepsis is known to
impair function of the sympathetic nervous system2,
which would subsequently reduce effectiveness of 
the baroreceptor reflex. Concomitantly, patients with
autonomic nervous system disease are exquisitely
sensitive to the effects of vasopressin3, and in cirrhotic
patients, infusion of low-dose vasopressin results in 
a sustained pressor response, manifested as a per-
sistently high systemic vascular resistance 30 minutes
after infusion4. This may be explained by impaired
sympathetic nervous system control of vascular tone
in the cirrhotic state.
Finally, I would like to draw attention to the fact
that vasopressin has also been used with considerable
success to optimize circulatory stability in the man-
agement of potential organ donors.
Brain death is accompanied by falls in the levels 
of essential hormones, particularly vasopressin5. A
regimen containing vasopressin for the replacement
of depleted hormones in brain dead donors restores
normal cardiovascular function, and can even
transform previously unsuitable organ donors into
acceptable ones6.
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